Filing Flows › 20/20 Biolabs (AIDX) › Q1 2026 › vs Q1 2025
20/20 Biolabs (AIDX) Q1 2026 vs Q1 2025 (year over year)
20/20 Biolabs's revenue fell $200K (-36%) from $554K in Q1 2025 to $353K in Q1 2026. The biggest changes: One Test −$161K (-34%); Bio Check −$35K (-62%); CLIAx −$4K (-15%).
20/20 Biolabs, Q1 2026: revenue $353K (-36% year over year), operating margin -408.4%, net loss $2.2M, operating cash flow −$1.3M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| One Test | $310K | $471K | −$161K | -34% |
| CLIAx | $22K | $25K | −$4K | -15% |
| Bio Check | $22K | $57K | −$35K | -62% |
| Revenue | $353K | $554K | −$200K | -36% |
| Net loss | $2.2M | $765K | $1.4M | +184% |
| Costs & expenses | $2.5M | $1.3M | $1.2M | +91% |
| Operating costs | $1.8M | $1.3M | $471K | +36% |
| Interest & other, net | $731K | −$8K | $739K | — |
| Cost of revenue | $290K | $388K | −$98K | -25% |
| Research & development | $153K | $137K | $17K | +12% |
| SG&A | $1.4M | $801K | $552K | +69% |
| Operating cash sources | $2.2M | $765K | $1.4M | +184% |
| Depreciation & amortization | $12K | $18K | −$6K | -31% |
| Share-based compensation | $128K | $130K | −$1K | -0.9% |
| Working capital & other | $745K | $129K | $616K | +478% |
| Cash used in operations | $1.3M | $488K | $801K | +164% |
| Net loss absorbed | $2.2M | $765K | $1.4M | +184% |
Questions
How much did 20/20 Biolabs's revenue grow year over year in Q1 2026?
20/20 Biolabs's revenue fell $200K (-36%) from $554K in Q1 2025 to $353K in Q1 2026.
What drove 20/20 Biolabs's revenue change in Q1 2026?
One Test −$161K (-34%); Bio Check −$35K (-62%); CLIAx −$4K (-15%).